Literature DB >> 33410106

Treatment of Disorders of Tone and Other Considerations in Pediatric Movement Disorders.

Stephen R Deputy1, Ann H Tilton2.   

Abstract

Pediatric movement disorders (PMDs) consist of a heterogeneous group of signs and symptoms caused by numerous neurological diseases. Different neurological disorders in children also share overlapping movement disorders making a diagnosis of the underlying cause of the movement disorder challenging. The similarity of the symptoms across multiple disease types suggests that there may be a final common motor pathway causing the overlapping movement disorders. There are numerous disorders in children associated with disturbances in tone and involuntary movements. This chapter will focus primarily on those disorders that involve abnormalities of tone and other important considerations of pediatric movement disorders. This chapter will address rating scales and goals for treatment and will include a review of symptomatic treatment and, where possible, the treatment of the underlying disease processes. The chapter will review representative disorders, including an inborn error of metabolism, an autoimmune disorder, and a group of neurodegenerative disorders. These examples demonstrate how the disorder's underlying pathophysiology results in a specific approach to the underlying disease and the associated conditions of tone and involuntary movements. Finally, the multiple treatment options for cerebral palsy and considerations of cerebral palsy mimics will be discussed.

Entities:  

Keywords:  Cerebral palsy; Childhood; Glucose transporter deficiency; NBIA; Pediatric movement disorders; Pediatrics; Sydenham chorea; Treatment

Year:  2021        PMID: 33410106      PMCID: PMC7851300          DOI: 10.1007/s13311-020-00984-6

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  68 in total

Review 1.  Constraint-induced movement therapy following stroke: a systematic review of randomised controlled trials.

Authors:  Sharon Hakkennes; Jennifer L Keating
Journal:  Aust J Physiother       Date:  2005

2.  Movement disorder-childhood rating scale: reliability and validity.

Authors:  Roberta Battini; Giuseppina Sgandurra; Elisa Petacchi; Andrea Guzzetta; Roberta Di Pietro; Maria T Giannini; Vincenzo Leuzzi; Eugenio Mercuri; Giovanni Cioni
Journal:  Pediatr Neurol       Date:  2008-10       Impact factor: 3.372

3.  Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.

Authors:  Thomas Klopstock; Fernando Tricta; Lynne Neumayr; Ivan Karin; Giovanna Zorzi; Caroline Fradette; Tomasz Kmieć; Boriana Büchner; Hannah E Steele; Rita Horvath; Patrick F Chinnery; Anna Basu; Clemens Küpper; Christiane Neuhofer; Bernadette Kálmán; Petr Dušek; Zuhal Yapici; Ian Wilson; Feng Zhao; Federica Zibordi; Nardo Nardocci; Christine Aguilar; Susan J Hayflick; Michael Spino; Andrew M Blamire; Penelope Hogarth; Elliott Vichinsky
Journal:  Lancet Neurol       Date:  2019-07       Impact factor: 44.182

Review 4.  Clinical presentation and management of dyskinetic cerebral palsy.

Authors:  Elegast Monbaliu; Kate Himmelmann; Jean-Pierre Lin; Els Ortibus; Laura Bonouvrié; Hilde Feys; R Jeroen Vermeulen; Bernard Dan
Journal:  Lancet Neurol       Date:  2017-09       Impact factor: 44.182

5.  Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial.

Authors:  R Gilmartin; D Bruce; B B Storrs; R Abbott; L Krach; J Ward; K Bloom; W H Brooks; D L Johnson; J R Madsen; J F McLaughlin; J Nadell
Journal:  J Child Neurol       Date:  2000-02       Impact factor: 1.987

6.  Medical treatment for spasticity in children with cerebral palsy.

Authors:  A G Nogen
Journal:  Childs Brain       Date:  1976

7.  Delayed-onset dystonia due to perinatal asphyxia: a prospective study.

Authors:  Igor Petrović; Christine Klein; Vladimir S Kostić
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

8.  Levetiracetam therapy for treatment of choreoathetosis in dyskinetic cerebral palsy.

Authors:  G F Vles; J G Hendriksen; A Visschers; L Speth; J Nicolai; J S H Vles
Journal:  Dev Med Child Neurol       Date:  2008-11-19       Impact factor: 5.449

9.  Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy.

Authors:  Terence D Sanger; Amy Bastian; Jan Brunstrom; Diane Damiano; Mauricio Delgado; Leon Dure; Deborah Gaebler-Spira; Alec Hoon; Jonathan W Mink; Sara Sherman-Levine; Leah J Welty
Journal:  J Child Neurol       Date:  2007-05       Impact factor: 1.987

10.  Reliability of Ashworth and Modified Ashworth scales in children with spastic cerebral palsy.

Authors:  Akmer Mutlu; Ayse Livanelioglu; Mintaze Kerem Gunel
Journal:  BMC Musculoskelet Disord       Date:  2008-04-10       Impact factor: 2.362

View more
  2 in total

1.  Therapeutic Advances in Movement Disorders.

Authors:  Caroline M Tanner; Jill L Ostrem
Journal:  Neurotherapeutics       Date:  2021-01-15       Impact factor: 7.620

2.  Psychopathological Impact in Patients with History of Rheumatic Fever with or without Sydenham's Chorea: A Multicenter Prospective Study.

Authors:  Alessandro Orsini; Thomas Foiadelli; Attilio Sica; Andrea Santangelo; Niccolò Carli; Alice Bonuccelli; Rita Consolini; Sofia D'Elios; Nicolò Loddo; Alberto Verrotti; Giuseppe Di Cara; Chiara Marra; Maria Califano; Anna Fetta; Marianna Fabi; Stefania Bergamoni; Aglaia Vignoli; Roberta Battini; Marta Mosca; Chiara Baldini; Nadia Assanta; Pietro Marchese; Gabriele Simonini; Edoardo Marrani; Francesca Felicia Operto; Grazia Maria Giovanna Pastorino; Salvatore Savasta; Giuseppe Santangelo; Virginia Pedrinelli; Gabriele Massimetti; Liliana Dell'Osso; Diego Peroni; Duccio Maria Cordelli; Martina Corsi; Claudia Carmassi
Journal:  Int J Environ Res Public Health       Date:  2022-08-25       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.